Effect of Imipramine on radiosensitivity of Prostate Cancer: An In Vitro Study. (21st October 2019)

• Record Type: Journal Article
• Authors: Barlaz Us, Songul; Sogut, Fatma; Yildirim, Metin; Yetkin, Derya; Yalin, Serap; Yilmaz, Sakir Necat; Comelekoglu, Ulku
• Is Part Of: Cancer investigation. Volume 37:Number 9(2019)
• Page Start: 489
• Page End: 500
• Publication Date: 2019-10-21
• Subjects: Imipramine -- prostate cancer -- radiotherapy -- cell index -- oxidative stress -- EAG1 channel; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2019.1662434
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: Prostate cancer is the most common cancer and leading cause of cancer death for males. Imipramine (IMI), which is a tricyclic antidepressant, has also been shown to has antineoplastic effect. This study was performed to investigate the radiosensitizing effect of IMI on DU145 prostate cancer cell. Cells were divided into 4 groups. Cell index, apoptotic activity, cell cycle arrest, oxidative stress and EAG1 channel currents were determined in all groups. Our findings showed that combined treatment with IMI and radiotherapy (RAD) did not enhance radiosensitivity of DU145 cells but as unexpected finding, treatment of IMI alone was more effective in DU145 cells.